



Express Mail No. EM245163208US

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/581,224
				Filing Date	November 19, 2007
				First Named Inventor	J. Kevin Day
				Art Unit	1634
				Examiner Name	Not yet assigned
Sheet	1	of	4	Attorney Docket Number	47675-194

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>1</sup> (if known)			
		US- 5565552	10-15-1996	Magda et al.	
		US- 5567810	10-22-1996	Weis et al.	
		US- 5574142	11-12-1996	Meyer, Jr. et al.	
		US- 5585481	12-17-1996	Arnold, Jr. et al.	
		US- 5587371	12-24-1996	Sessler et al.	
		US- 5597696	01-28-1997	Linn et al.	
		US- 5786146	07-28-1998	Herman et al.	
		US- 5958773	09-28-1999	Monia et al.	
		US- 6251594	06-26-2001	Gonzalogo et al.	
		US- 6265171	07-24-2001	Herman et al.	
		US- 6331393	12-18-2001	Laird et al.	
		US 2003/0013091	01-16-2003	Dimitrov	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
		EP 03090414.8	12-01-2003	Epigenomics AG		
		EP 04090040.9	02-10-2004	Epigenomics AG		
		EP 04090187.8	05-10-2004	Epigenomics AG		
		EP 04090292.6	07-21-2004	Epigenomics AG		
		WO 95/00669	01-05-1995	Pharmacia Biotech AB		
		WO 95/15373	06-08-1995	McGill University		
		WO 97/46705	12-11-1997	Johns Hopkins		
		WO 99/28498	06-10-1999	Epigenomics GmbH		
		WO 99/55905	11-04-1999	Commonwealth Scientific and Industrial Research		
		WO 00/26401	05-11-2000	Johns Hopkins		
		WO 01/76451	10-18-2001	Epigenomics AG		

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04 <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Application Number	10/581,224
		Filing Date	November 19, 2007
		First Named Inventor	J. Kevin Day
		Art Unit	1634
		Examiner Name	Not yet assigned
		Attorney Docket Number	47675-194
Sheet	2	of	4

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
		WO 02/00926	01-03-2002	Epigenomics AG		
		WO 02/18632	03-07-2002	Epigenomics AG		
		WO 02/081749	10-17-2002	University of Southern California		
		WO 02/103041	12-27-2002	Epigenomics AG		
		WO 02/103042	12-27-2002	Epigenomics AG		
		WO 03/044232	05-30-2003	Johns Hopkins		
		WO 2004/000463	12-31-2003	Epigenomics AG		
NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>2</sup>
		BELYAVSKY et al., "PCR-based cDNA library construction: general cDNA libraries at the level of a few cells," Nucleic Acids Research, 1989, pp. 2919-2932, Volume 17, No. 8				
		BOWTELL, "Options available - from start to finish - for obtaining expression data by microarray," Nature Genetics Supplement, January 1999, pp. 25-32, Volume 21				
		CAIRNS et al., "Molecular Detection of Prostate Cancer in Urine by GSTP1 Hypermethylation," Clinical Cancer Research, September 2001, pp. 2727-2730, Volume 7				
		DATABASE, EMBL, Human Genomic Sequence, April 30, 2002, Database Accession No. AC063960, XP002338678, abstract				
		DATABASE, EMBL, Human EST, December 22, 1999, Database Accession No. AI702131, XP002338679, abstract				
		DATABASE, EMBL, Human EST, May 24, 2000, Database Accession No. AW853489, XP002338680, abstract				
		DATABASE, EMBL, Human EST, December 1, 2000, Database Accession No. BF432721, XP002338681, abstract				
		DATABASE, EMBL, Human EST, March 22, 2003, Database Accession No. BX374481, XP002338682, abstract				
		EADS et al., "CpG Island Hypermethylation in Human Colorectal Tumors Is Not Associated with DNA Methyltransferase Overexpression," Cancer Research, May 15, 1999, pp. 2302-2306, Volume 59				
		FEIL et al., "Methylation analysis on individual chromosomes: improved protocol for bisulphite genomic sequencing," Nucleic Acids Research, 1994, pp. 695-696, Volume 22, Number 4				
		FROMMER et al., "A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands," PNAS, March 1992, pp. 1827-1831, Volume 89				

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04 <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/581,224
				Filing Date	November 19, 2007
				First Named Inventor	J. Kevin Day
				Art Unit	1634
				Examiner Name	Not yet assigned
Sheet	3	of	4	Attorney Docket Number	47675-194

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		GALFRE et al., "Preparation of Monoclonal Antibodies: Strategies and Procedures," Methods in Enzymology, pp. 3-46, Volume 73	
		GONZALGO et al., "Identification and Characterization of Differentially Methylated Regions of Genomic DNA by Methylation-sensitive Arbitrarily Primed PCR," Cancer Research, February 15, 1997, pp. 594-599, Volume 57	
		GONZALGO et al., "Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE), Nucleic Acids Research, 1997, pp. 2529-2531, Volume 25, No. 12	
		GRIGG et al., "Sequencing 5-Methylcytosine Residues in Genomic DNA," BioEssays, June 1994, pp. 431-436, Volume 16, Number 6	
		GUT et al., "DNA and Matrix Assisted Laser Desorption Ionization Mass Spectrometry," Molecular Biology: Current Innovations and Future Trends, 1995, pp. 147-157, Horizon Scientific Press, Wymondham, United Kingdom	
		GUT et al., "A procedure for selection DNA alkylation and detection by mass spectrometry," Nucleic Acids Research, 1995, pp. 1367-1373, Volume 23, No. 8	
		HARDEN et al., "Quantitative GSTP1 Methylation and the Detection of Prostate Adenocarcinoma in Sextant Biopsies," Journal of the National Cancer Institute, November 5, 2003, pp. 1634-1637, Volume 95, No. 21	
		HEID et al., "Real Time Quantitative PCR," Genome Research, 1996, pp. 986-994, Volume 6	
		HERMAN et al., "Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands," September 1996, pp. 9821-9826, Volume 93	
		KARAS et al., "Laser Desorption Ionization of Proteins with Molecular Masses Exceeding 10 000 Daltons," Analytical Chemistry, October 15, 1988, pp. 2299-2301, Volume 60, No. 20	
		KOEHLER et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature, August 7, 1975, pp. 495-497, Volume 256	
		KRUG et al., "First-Strand cDNA Synthesis Primed with Oligo(dT)," Methods in Enzymology, 1987, pp. 316-325, Volume 152	
		LIPSHUTZ et al., "High density synthetic oligonucleotide arrays," Nature Genetics Supplement, January 1999, pp. 20-24, Volume 21	
		MARTIN et al., "Genomic sequencing indicates a correlation between DNA hypomethylation in the 5' region of the pS2 gene and its expression in human breast cancer cell lines," Gene, 1995, pp. 261-265, Volume 157	
		OLEK et al., "A modified and improved method for bisulphite based cytosine methylation analysis," Nucleic Acids Research, 1996, pp. 5064-5066, Volume 24, No. 24	
		OLEK et al., "The pre-implantation ontogeny of the H19 methylation imprint," Nature Genetics, November 1997, pp. 275-276, Volume 17	
		REIN et al., "Identifying 5-methylcytosine and related modifications in DNA genomes," Nucleic Acids Research, 1998, pp. 2255-2264, Volume 26, Number 10	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04 <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Application Number	10/581,224
		Filing Date	November 19, 2007
		First Named Inventor	J. Kevin Day
		Art Unit	1634
		Examiner Name	Not yet assigned
Sheet	4	of	4
		Attorney Docket Number	47675-194

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		SADRI et al., "Rapid analysis of DNA methylation using new restriction enzyme sites created by bisulfite modification," Nucleic Acids Research, 1996, pp. 5058-5059, Volume 24, No. 24	
		SANGER et al., "DNA sequencing with chain-terminating inhibitors," PNAS, December 1977, pp. 5463-5467, Volume 74, Number 12	
		SANTOURLIDIS et al., "High Frequency of Alterations in DNA Methylation in Adenocarcinoma of the Prostate," The Prostate, 1999, pp. 166-174, Volume 39	
		STITES et al., "Clinical Laboratory Methods for Detection of Antigens and Antibodies," Basic and Clinical Immunology, 7 <sup>th</sup> ed., 1991, pp. 217-262, Appleton & Lange, Norwalk, Conn.	
		TOYOTA et al., "Identification of Differentially Methylated Sequences in Colorectal Cancer by Methylated CpG Island Amplification," Cancer Research, May 15, 1999, pp. 2307-2312, Volume 59	
		VAN DER KROL et al., "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences," BioTechniques, November-December 1988, pp. 958-976, Volume 6, No. 10	
		VIS et al., "Feasibility of Assessment of Promoter Methylation of the CD44 Gene in Serum of Prostate Cancer Patients," Molecular Urology, 2001, pp. 199-203, Volume 5, No. 4	
		XIONG et al., "COBRA: a sensitive and quantitative DNA methylation assay," Nucleic Acids Research, 1997, pp. 2532-2534, Volume 25, No. 12	
		YAMADA et al., "Aberrant methylation of the vascular endothelial growth factor receptor-1 gene in prostate cancer," Cancer Science, June 2003, pp. 536-539, Volume 94, No. 6	
		YU et al., "Specific Inhibition of PCR by Non-Extendable Oligonucleotides Using a 5' to 3' Exonuclease-Deficient DNA Polymerase," BioTechniques, October 1997, pp. 714-720, Volume 23	
		ZESCHNIGK et al., "Imprinted segments in the human genome: different DNA methylation patterns in the Prader-Willi/Angelman syndrome region as determined by the genomic sequencing method," Human Molecular Genetics, 1997, pp. 387-395, Volume 6, No. 3	
		ZESCHNIGK et al., "A single-tube PCR test for the diagnosis of Angelman and Prader-Willi syndrome based on allelic methylation differences at the SNRPN locus," European Journal of Human Genetics, March-April 1997, pp. 94-98, Volume 5, No. 2	
		ZON, "Oligonucleotide Analogues as Potential Chemotherapeutic Agents," Pharmaceutical Research, September 1988, pp. 539-549, Volume 5, No. 9	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04 <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.